103 related articles for article (PubMed ID: 38687749)
1. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
2. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
[TBL] [Abstract][Full Text] [Related]
3. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
[TBL] [Abstract][Full Text] [Related]
4. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract][Full Text] [Related]
5. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
[TBL] [Abstract][Full Text] [Related]
6. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Han H; Fillat C; Kinugasa Y; Goel A
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297310
[TBL] [Abstract][Full Text] [Related]
7. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.
Sato N; Kohi S; Hirata K; Goggins M
Cancer Sci; 2016 May; 107(5):569-75. PubMed ID: 26918382
[TBL] [Abstract][Full Text] [Related]
8. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
Lee JW; Komar CA; Bengsch F; Graham K; Beatty GL
Curr Protoc Pharmacol; 2016 Jun; 73():14.39.1-14.39.20. PubMed ID: 27248578
[TBL] [Abstract][Full Text] [Related]
9. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.
Mao X; Xu J; Xiao M; Liang C; Hua J; Liu J; Wang W; Yu X; Meng Q; Shi S
Redox Biol; 2024 May; 73():103200. PubMed ID: 38781729
[TBL] [Abstract][Full Text] [Related]
10. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
[TBL] [Abstract][Full Text] [Related]
11. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
12. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract][Full Text] [Related]
13. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
